公开(公告)号：EP0238198A2

公开(公告)日：1987-09-23

申请号：EP87301257.9

申请日：1987-02-13

Applicant: Habib, Nagy Adly

Inventor： Wood, Christopher Barry ,  Apostolov, Kosta ,  Habib, Nagy Adly ,  Barker, William Roland

IPC: A61K31/20

CPC classification number: A61K31/20 ,  A61K31/23

Abstract: The invention is concerned with the use of certain fatty acids and inhibitors of an enzyme in effecting modifications to the lipid structure of cell membranes and in modifying the degree of expression of cell receptors and antigen determinants. The invention also relates to the formulation of pharmaceutical compositions and medicaments and to such products per se; to the treatment of a variety of clinical and veterinary disorders associated with a lowering of the saturation index of cell membranes, including malignancies, viral disorders and AIDS; and to the use of the active materials of the invention in the relief of pain and in bioengineering processes.
The active principals in the present invention are saturated fatty acids having from 12 to 28 carbon atoms in the alkyl chain, e.g. stearic acid, or pharmaceutically acceptable derivatives thereof; and inhibitors of the enzyme A-9 desaturase, e.g. sterculic acid and malvalic acid or pharmacologically active derivatives or analogues thereof. Interferon is also used in modifying the expression of cell receptors and antigenic determinants.

Abstract translation: 本发明在实现修改细胞膜的脂质结构以及在修改细胞受体和抗原决定簇的表达程度涉及使用某些脂肪酸和酶的抑制剂来。 因此，本发明涉及药物组合物和药物和的配方，以搜寻产品本身; 于各种用降低细胞膜，包括恶性肿瘤，病毒疾病和艾滋病的饱和指数的相关的临床和兽医疾病的治疗; 并使用在缓解疼痛的本发明的活性材料制成，并且在生物工程处理。 在本发明的活性主体是饱和的具有12至28个碳原子在烷基链脂肪酸，例如 硬脂酸，或其药学上可接受的衍生物; 和酶DELTA -9去饱和酶的抑制剂，E.G. 苹婆酸和锦葵酸或药理活性的衍生物或其类似物。 因此干扰素在修饰细胞受体和抗原决定簇的表达使用。

公开(公告)号：EP0238198A3

公开(公告)日：1990-05-30

申请号：EP87301257.9

申请日：1987-02-13

Applicant: Habib, Nagy Adly

Inventor： Wood, Christopher Barry ,  Apostolov, Kosta ,  Habib, Nagy Adly ,  Barker, William Roland

IPC: A61K31/20

CPC classification number: A61K31/20 ,  A61K31/23

Abstract: The invention is concerned with the use of certain fatty acids and inhibitors of an enzyme in effecting modifications to the lipid structure of cell membranes and in modifying the degree of expression of cell receptors and antigen determinants. The invention also relates to the formulation of pharmaceutical compositions and medicaments and to such products per se; to the treatment of a variety of clinical and veterinary disorders associated with a lowering of the saturation index of cell membranes, including malignancies, viral disorders and AIDS; and to the use of the active materials of the invention in the relief of pain and in bioengineering processes. The active principals in the present invention are saturated fatty acids having from 12 to 28 carbon atoms in the alkyl chain, e.g. stearic acid, or pharmaceutically acceptable derivatives thereof; and inhibitors of the enzyme A-9 desaturase, e.g. sterculic acid and malvalic acid or pharmacologically active derivatives or analogues thereof. Interferon is also used in modifying the expression of cell receptors and antigenic determinants.

Abstract translation: 本发明涉及使用某些脂肪酸和酶的抑制剂来实现细胞膜脂质结构的修饰和修饰细胞受体和抗原决定簇的表达程度。 本发明还涉及药物组合物和药物及其制品本身; 治疗与降低细胞膜饱和指数相关的各种临床和兽医疾病，包括恶性肿瘤，病毒性疾病和艾滋病; 以及使用本发明的活性物质缓解疼痛和生物工程过程。 本发明中的活性成分是在烷基链中具有12至28个碳原子的饱和脂肪酸，例如。 硬脂酸或其药学上可接受的衍生物; 和DELTA-9去饱和酶的抑制剂，例如。 苹果酸和苹果酸或其药理学活性衍生物或类似物。 干扰素也用于修饰细胞受体和抗原决定簇的表达。

公开(公告)号：EP0348042A1

公开(公告)日：1989-12-27

申请号：EP89305221.7

申请日：1989-05-23

Applicant: Wood, Christopher Barry ,  Habib, Nagy Adly

Inventor： Wood, Christopher Barry ,  Habib, Nagy Adly

IPC: A61K35/74 ,  C12N5/00

CPC classification number: A61Q19/08 ,  A61K8/99 ,  A61K35/744 ,  A61Q19/00 ,  C12P1/04 ,  C12R1/265

Abstract: A method of modifying the lipid structure of cell membranes is disclosed which utilises the supernatant derived from a culture of Micrococcus cryophilus (ATCC 15174) or an extract therefrom. This method has utility in veterinary and clinical treatment of conditions characterised by an increase in the saturation index. Compositions incorporating the active ingredient are also provided.

Abstract translation: 公开了一种修饰细胞膜脂质结构的方法，该方法利用了来自冷冻微球菌（ATCC 15174）的培养物的上清液或其提取物。 该方法在兽医和临床治疗中具有以饱和指数增加为特征的病症。 还提供了含有活性成分的组合物。

公开(公告)号：EP0257081A1

公开(公告)日：1988-03-02

申请号：EP87901532.0

申请日：1987-02-16

Applicant: Habib, Nagy Adly

Inventor： WOOD, Christopher, Barry ,  APOSTOLOV, Kosta ,  BARKER, William, Roland ,  HABIB, Nagy Adly

IPC: C07C57 ,  A61K31 ,  A61P31 ,  A61P35 ,  C07C51 ,  C07C53 ,  C07C67

CPC classification number: A61K31/23 ,  A61K31/20

Abstract: Utilisation de certains acides gras pour produire des modifications de la structure lipidique des membranes cellulaires. L'invention se rapporte également à la formulation de compositions pharmaceutiques et de médicaments et à ses produits en soi; au traitement d'un ensemble de troubles cliniques et vétérinaires associés à l'élévation de l'indice de saturation des membranes cellulaires, notamment de troubles nerveux comprenant la sclérose en plaques et la schizophrénie; ainsi qu'à l'utilisation des substances actives faisant l'objet de l'invention dans le traitement desdits troubles. Les principes actifs décrits sont des acides gras mono-insaturés présentant de 12 à 28 atomes de carbone dans la chaîne alkyle, par exemple l'acide oléique, ou des dérivés pharmaceutiquement acceptables.

公开(公告)号：WO0204026A2

公开(公告)日：2002-01-17

申请号：PCT/GB0103119

申请日：2001-07-11

Applicant: HABIB NAGY ADLY

Inventor： HABIB NAGY ADLY

IPC: A61K48/00

CPC classification number: A61K48/0058

Abstract: Hypomethylation of the L1 retrotransposon sequence is demonstrated in cancerous cells. The invention provides the use of a retrotransposon, in particular the L1 sequence, as a promoter to control gene expression in a method of gene therapy.

Abstract translation: 在癌细胞中证实了L1反转录转座子序列的低甲基化。 本发明提供了逆转录转座子，特别是L1序列在基因治疗方法中用作控制基因表达的启动子的用途。

公开(公告)号：WO0004945A3

公开(公告)日：2001-06-21

申请号：PCT/GB9902389

申请日：1999-07-22

Applicant: IMP COLLEGE INNOVATIONS LTD ,  HABIB NAGY ADLY ,  SANGSTER ALAN JOHN

Inventor： HABIB NAGY ADLY ,  SANGSTER ALAN JOHN

IPC: G08C19/00 ,  A61B5/00 ,  A61B10/00 ,  A61B19/00 ,  A61F2/02 ,  A61F7/12 ,  A61G11/00 ,  A61N1/372 ,  A61N1/378 ,  G08C17/00 ,  H01Q1/24

CPC classification number: H01Q1/248 ,  A61B5/0031 ,  A61F2250/0002 ,  A61N1/37223 ,  A61N1/3787

Abstract: Methods of and devices for monitoring the treatment of a human or non-human animal are disclosed. These involve a sensor which is adapted (a) to receive and to rectify an electromagnetic (e.g. radio) signal directed from outside the body towards it, and (b) to transmit data relating to treatment parameters by wireless telemetry to a receiver external to the body of the human or non-human animal. The data transmitted by the sensor is then processed to provide information on the treatment.

Abstract translation: 公开了用于监测人或非人动物的治疗的方法和装置。 这些传感器涉及一种传感器，其适于（a）接收和整流从身体外部向其指向的电磁（例如无线电）信号，以及（b）通过无线遥测将有关治疗参数的数据传送到 人类或非人类动物的身体。 然后处理由传感器发送的数据以提供关于治疗的信息。

公开(公告)号：WO1987004926A2

公开(公告)日：1987-08-27

申请号：PCT/GB1987000111

申请日：1987-02-16

Applicant: HABIB, Nagy, Adly ,  WOOD, Christopher, Barry ,  APOSTOLOV, Kosta ,  BARKER, William, Roland

IPC: A61K31/20

CPC classification number: A61K31/23 ,  A61K31/20

Abstract: Use of certain fatty acids in effecting modifications to the lipid structure of cell membranes. The invention also relates to the formulation of pharmaceutical compositions and medicaments and to such products per se; to the treatment of a variety of clinical and veterinary disorders associated with elevation of the saturation index of cell membranes, including nervous disorders including multiple sclerosis and schizophrenia; and to the use of the active materials of the invention in the treatment thereof. The active principles in the present invention are mono-unsaturated fatty acids having from 12 to 28 carbon atoms in the alkyl chain, e.g. oleic acid, or pharmaceutically acceptable derivatives thereof.

Abstract translation: 使用某些脂肪酸来改变细胞膜的脂质结构。 本发明还涉及药物组合物和药物及其制品本身; 治疗与提高细胞膜饱和指数相关的各种临床和兽医疾病，包括神经障碍，包括多发性硬化和精神分裂症; 以及本发明的活性物质在其处理中的用途。 本发明中的活性成分是在烷基链中具有12至28个碳原子的单不饱和脂肪酸，例如， 油酸或其药学上可接受的衍生物。

公开(公告)号：WO2008084239A3

公开(公告)日：2008-11-13

申请号：PCT/GB2008000084

申请日：2008-01-11

Applicant: HABIB MEDICAL LTD ,  HABIB NAGY

Inventor： HABIB NAGY

IPC: A61B18/14

CPC classification number: A61B18/082 ,  A61B18/1492 ,  A61B2017/00867 ,  A61B2018/00214 ,  A61B2018/00267 ,  A61B2018/1435 ,  A61B2018/1467 ,  A61B2018/1495 ,  C08L2201/12

Abstract: Devices suitable for insertion into a hollow anatomical structure within a patient for the purpose of ablating tissue within or surrounding the hollow structure so as to induce occlusion of the hollow structure are provided. The devices are in the form of guidewires with functional tips, that comprise at least one heating module, at their distal ends. The devices of the invention are suitable for occluding hollow anatomical structures selected from vasculature or from non-vascular ducts and tubes, via percutaneous, laparoscopic or endoscopic routes of access. Methods of using the devices in the treatment of patients are also described.

Abstract translation: 提供了适于插入患者体内的中空解剖结构中以便消融中空结构内或周围的组织以便引起中空结构闭塞的装置。 这些装置是具有功能尖端的导丝的形式，其在其远端包括至少一个加热模块。 本发明的装置适用于通过经皮，腹腔镜或内窥镜进入途径阻塞选自脉管系统或来自非血管导管和管道的中空解剖结构。 还描述了使用该装置治疗患者的方法。

公开(公告)号：WO2008009972A3

公开(公告)日：2008-08-07

申请号：PCT/GB2007002793

申请日：2007-07-23

Applicant: EMCISION LTD ,  HABIB NAGY ,  PACEY ANDREW ROBERT

Inventor： HABIB NAGY ,  PACEY ANDREW ROBERT

IPC: A61B18/14

CPC classification number: A61B18/1492 ,  A61B18/1445 ,  A61B18/1477 ,  A61B2018/1425 ,  A61B2018/144 ,  A61B2018/1475

Abstract: A flexible RF device (1) can be deployed through a flexible endoscope. An electrode structure has a central electrode (12) and outer electrode (11). Flexible electrodes (30), circular electrodes (51, 53) and circular loop assemblies (55, 56) with different diameters are also disclosed, as well a tweezer electrodes (41) with pads (43) for increasing contact area. Retractable electrodes (100) are also disclosed.

Abstract translation: 柔性射频设备（1）可以通过柔性内窥镜展开。 电极结构具有中心电极（12）和外部电极（11）。 还公开了具有不同直径的柔性电极（30），圆形电极（51,53）和圆形环组件（55,56）以及具有用于增加接触面积的垫（43）的镊子电极（41）。 还公开了可伸缩电极（100）。

公开(公告)号：WO2007038201A1

公开(公告)日：2007-04-05

申请号：PCT/US2006/036820

申请日：2006-09-21

Applicant: BIOENVISION, INC. ,  WOOD, Christopher ,  HABIB, Nagy

Inventor： WOOD, Christopher ,  HABIB, Nagy

IPC: A61K31/5415 ,  A61P33/00 ,  A61P33/02 ,  A61P33/06

CPC classification number: A61K45/06 ,  A61K9/2846 ,  A61K9/2866 ,  A61K31/185 ,  A61K31/29 ,  A61K31/4706 ,  A61K31/513 ,  A61K31/5415 ,  A61K41/0057 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/415 ,  Y02A50/491 ,  A61K2300/00 ,  A61K41/00

Abstract: A method for using thiazine dyes, especially methylene blue, alone or in combination with low levels of light, to treat parasitic diseases is described. Examples of useful thiazine dyes are methylene blue, azure A, azure C, toluidine, and thionine. The preferred dye is methylene blue, administered orally twice a day. Since methylene blue absorbs in the red wavelengths, i.e., approximately 670 nm, which penetrates tissue much better than other lower wavelengths, light penetrating the skin to the capillaries at the surface can be used to enhance the activity of the dye. The thiazine dye can be provided in combination with other known antibiotics, anti-inflammatories, anti-parasitics, antifungals, and antivirals.

Abstract translation: 描述了使用噻嗪染料，特别是亚甲蓝单独或与低水平的光结合来治疗寄生虫病的方法。 有用的噻嗪染料的实例是亚甲基蓝，天蓝A，天蓝C，甲苯胺和硫
素。 优选的染料是亚甲基蓝，每天口服两次。 由于亚甲基蓝以相对于其它较低波长穿透组织的红色波长即大约670nm吸收，所以可以使用将表皮渗入皮肤到达毛细管的光来提高染料的活性。 噻嗪染料可以与其他已知的抗生素，抗炎剂，抗寄生虫，抗真菌剂和抗病毒药物组合提供。